XML 23 R14.htm IDEA: XBRL DOCUMENT
v3.23.3

INTANGIBLE ASSETS AND GOODWILL | 9 Months Ended
--- | ---
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
INTANGIBLE ASSETS AND GOODWILL | INTANGIBLE ASSETS AND GOODWILL Intangible Assets The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of September 30, 2023:
(In thousands) |  | Weighted Average Remaining Life (Years) |  | Cost |  | Accumulated Amortization |  | Net Balance at September 30, 2023
Finite-lived intangible assets |  |  |  |  |  |  |  |
Trade name |  | 11.8 |  | $ | 104,000 |  |  | $ | (26,090) |  |  | $ | 77,910 |
Customer relationships |  | 7.3 |  | 4,000 |  |  | (778) |  |  | 3,222 |
Patents and licenses |  | 4.3 |  | 11,542 |  |  | (9,237) |  |  | 2,305 |
Acquired developed technology (1) |  | 7.5 |  | 887,389 |  |  | (307,519) |  |  | 579,870 |
Total finite-lived intangible assets |  |  |  | 1,006,931 |  |  | (343,624) |  |  | 663,307 |
In-process research and development |  | n/a |  | 1,250,000 |  |  | — |  |  | 1,250,000 |
Total intangible assets |  |  |  | $ | 2,256,931 |  |  | $ | (343,624) |  |  | $ | 1,913,307 |
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:
(In thousands) |  | Weighted Average Remaining Life (Years) |  | Cost |  | Accumulated Amortization |  | Net balance at December 31, 2022
Finite-lived intangible assets |  |  |  |  |  |  |  |
Trade name |  | 12.5 |  | $ | 104,000 |  |  | $ | (20,653) |  |  | $ | 83,347 |
Customer relationships |  | 8.0 |  | 4,000 |  |  | (444) |  |  | 3,556 |
Patents and licenses |  | 4.2 |  | 11,542 |  |  | (8,152) |  |  | 3,390 |
Acquired developed technology (1) |  | 7.8 |  | 861,474 |  |  | (245,527) |  |  | 615,947 |
Total finite-lived intangible assets |  |  |  | 981,016 |  |  | (274,776) |  |  | 706,240 |
In-process research and development |  | n/a |  | 1,250,000 |  |  | — |  |  | 1,250,000 |
Total intangible assets |  |  |  | $ | 2,231,016 |  |  | $ | (274,776) |  |  | $ | 1,956,240 |
______________ (1)The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. As of September 30, 2023 the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands) |  |
2023 (remaining three months) |  | $ | 23,311 |
2024 |  | 92,908 |
2025 |  | 91,860 |
2026 |  | 90,800 |
2027 |  | 90,800 |
Thereafter |  | 273,628 |
|  | $ | 663,307 |
The Company’s acquired intangible assets are being amortized on a straight-line basis over their estimated useful lives. On August 2, 2022, the Company completed a sale of the developed technology intangible asset related to the GPS test to MDxHealth SA (“MDxHealth”), which was measured using the income approach to determine the fair value. The gross value of the intangible asset was $59.0 million with accumulated amortization of $16.1 million as of the closing date, resulting in a carrying value of $42.9 million, which was derecognized from intangible assets, net in the condensed consolidated balance sheets upon completion of the divestiture. Refer to the Company’s 2022 Form 10-K for further information on the sale. During the third quarter of 2022, the remaining carrying value of $2.0 million related to the supply agreement intangible asset acquired as part of the combination with Genomic Health, Inc. (“Genomic Health”) was recorded as a non-cash, pre-tax impairment loss due to the termination of the agreement. During the second quarter of 2022, the Company recorded a non-cash, pre-tax impairment loss of $6.6 million related to the acquired developed technology intangible asset acquired as a result of the acquisition of Paradigm Diagnostics, Inc. due to lower than anticipated performance of the underlying product. The impairment charges recorded are included in impairment of long-lived assets in the condensed consolidated statement of operations. Goodwill The change in the carrying amount of goodwill for the periods ended September 30, 2023 and December 31, 2022 is as follows:
(In thousands) |  |
Balance, January 1, 2022 |  | $ | 2,335,172 |
OmicEra acquisition |  | 10,809 |
PreventionGenetics acquisition adjustment |  | (58) |
Effects of changes in foreign currency exchange rates (1) |  | 117 |
Balance, December 31, 2022 |  | 2,346,040 |
Resolution Bioscience acquisition (2) |  | 20,569 |
Effects of changes in foreign currency exchange rates (1) |  | (95) |
Balance September 30, 2023 |  | $ | 2,366,514 |
______________ (1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. (2)Refer to Note 16 for further discussion on the Company’s acquisition of Resolution Bioscience, Inc. There were no impairment losses for the three and nine months ended September 30, 2023 and 2022.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration